Literature DB >> 1617394

Asthma. Eosinophils and neutrophils.

A B Kay1, C J Corrigan.   

Abstract

Eosinophils are strongly implicated as a major proinflammatory cell in the pathogenesis of asthma. Basic proteins from the crystalloid granule may be responsible for damage to mucosal epithelium whereas membrane-derived lipid mediators (particularly platelet activating factor and leukotriene C4) might directly influence bronchial smooth muscle contraction, microvascular permeability and mucus hypersecretion. The numbers of eosinophils and their products correlated with the severity of disease whereas successful treatment is usually associated with a resolution of local eosinophilia. Neutrophils may also be implicated in the pathogenesis of asthma but the evidence that this cell per se plays an important role remains controversial. Neutrophil products have the potential for altering airway function. More research is required to define the precise role of this cell type in asthma. It needs to be emphasised that the inflammation associated with bronchial asthma is complex and involves several cell types (i.e. T lymphocytes, mast cells and macrophages) in addition to the eosinophil and neutrophil.

Entities:  

Mesh:

Year:  1992        PMID: 1617394     DOI: 10.1093/oxfordjournals.bmb.a072541

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  19 in total

1.  Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily.

Authors:  K A Larson; E V Olson; B J Madden; G J Gleich; N A Lee; J J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 2.  Molecular biology and genetics of allergy and asthma.

Authors:  G G Anderson; J F Morrison
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

3.  Differential modulation by betamethasone of allergen-induced cell influx and cell peroxidase in guinea-pig lungs.

Authors:  M Yeadon; A A Petrovic; S J Getting; A N Payne
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

Review 4.  New perspectives on basic mechanisms in lung disease. 3. Drug intervention in asthma: present and future.

Authors:  V A Alabaster; B A Moore
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

5.  Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells.

Authors:  Gautam Damera; Hengjiang Zhao; Miao Wang; Michael Smith; Christopher Kirby; William F Jester; John A Lawson; Reynold A Panettieri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-06       Impact factor: 5.464

6.  LPS-induced 111In-eosinophil accumulation in guinea-pig skin: evidence for a role for TNF-alpha.

Authors:  V B Weg; D T Walsh; L H Faccioli; T J Williams; M Feldmann; S Nourshargh
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

7.  Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals.

Authors:  Kenichiro Maeda; Alex Malykhin; Brittany N Teague-Weber; Xiao-Hong Sun; A Darise Farris; K Mark Coggeshall
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

8.  Blood eosinophils, leukotriene C4 generation, and bronchial hyperreactivity in formerly preterm infants.

Authors:  U Schauer; S Alefsen; R Jäger; F Riedel; C H Rieger
Journal:  Arch Dis Child       Date:  1994-12       Impact factor: 3.791

9.  Investigation of the endogenous chemoattractants involved in 111In-eosinophil accumulation in passive cutaneous anaphylactic reactions in the guinea-pig.

Authors:  V B Weg; M L Watson; L H Faccioli; T J Williams
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

10.  Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice.

Authors:  Umesh C S Yadav; Kota V Ramana; Leopoldo Aguilera-Aguirre; Istvan Boldogh; Hamid A Boulares; Satish K Srivastava
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.